Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Annual Report and Accounts

24 Mar 2011 09:02

RNS Number : 5438D
Cathay International Holdings Ld
24 March 2011
 

Cathay International Holdings Limited

("Cathay" or the "Company")

Annual Report and Accounts

Hong Kong, 24 March 2011 - Cathay International Holdings Limited (LSE: CTI.L), an investment holding company and a leading investor in the growing healthcare sector in the People's Republic of China, today announces that that its Annual Report and Accounts for the financial year ended 31 December 2010 together with the Notice of Annual General Meeting ("AGM") and Form of Proxy for its forthcoming AGM were posted to shareholders yesterday.

Electronic copies of the above documents have been submitted to the National Storage Mechanism ("NSM") and will shortly be available for inspection at www.hemscott.com/nsm.do and on the Company's website at www.cathay-intl.com.hk.

For further enquiries, please contact:

For further enquiries, please contact:

Cathay International Holdings Limited

Eric Siu (Finance Director)

Patrick Sung (Director and Controller)

Tel: +852 2828 9289

M:Communications

Mary-Jane Elliott / Nick Francis / Amber Bielecka

Tel: +44 (0) 207 920 2330

 

 

About Cathay International Holdings Limited

Cathay International Holdings Limited (CIH), focused on the People's Republic of China (PRC), is an investment holding company and a leading investor in the growing healthcare sector in China. The Group employs more than 2000 people across the PRC, including over 30 specialist corporate and business development staff based at the holding company's headquarters in Hong Kong and Shenzhen.

The Group aims to identify investment opportunities with emphasis on high growth healthcare markets and build them into market sector leaders, with a clear exit strategy. The Group has demonstrated a strong track record of identifying high-growth potential investment opportunities in this area including: Lansen Group, a leading specialty pharmaceutical company focused on rheumatology and Haotian Group, a company engaged in the manufacture, marketing and sale of key active ingredients for healthcare products, including inositol. To complement its healthcare portfolio, CIH has an R&D business focused on bringing new products to the growing Chinese market.

The Group also has a private equity investment arm focused on minority investment opportunities and a hotel investment.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACSSEFSULFFSESD

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.